Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Downgraded by BidaskClub
BidaskClub lowered shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) from a strong-buy rating to a buy rating in a research note released on Wednesday.
Other research analysts have also recently issued research reports about the stock. TheStreet cut shares of Pieris Pharmaceuticals from a c- rating to a d- rating in a report on Monday, June 12th. Rodman & Renshaw assumed coverage on shares of Pieris Pharmaceuticals in a report on Tuesday, May 30th. They set a buy rating and a $9.00 target price for the company. Finally, Oppenheimer Holdings, Inc. set a $9.00 price target on shares of Pieris Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, April 12th. Four research analysts have rated the stock with a buy rating, Pieris Pharmaceuticals presently has an average rating of Buy and a consensus target price of $8.00.
Pieris Pharmaceuticals (PIRS) opened at 5.32 on Wednesday. The stock’s 50 day moving average is $5.16 and its 200-day moving average is $3.36. The company’s market cap is $229.12 million. Pieris Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $6.20.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by $0.35. Pieris Pharmaceuticals had a negative return on equity of 95.10% and a negative net margin of 449.33%. The business had revenue of $1.34 million for the quarter, compared to analyst estimates of $32.30 million. Analysts predict that Pieris Pharmaceuticals will post ($0.69) earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC bought a new position in shares of Pieris Pharmaceuticals during the second quarter valued at $162,000. Creative Planning raised its position in shares of Pieris Pharmaceuticals by 8.3% in the second quarter. Creative Planning now owns 65,000 shares of the biotechnology company’s stock valued at $329,000 after buying an additional 5,000 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Pieris Pharmaceuticals during the first quarter valued at $661,000. Finally, Sphera Funds Management LTD. raised its position in shares of Pieris Pharmaceuticals by 23.5% in the first quarter. Sphera Funds Management LTD. now owns 1,000,000 shares of the biotechnology company’s stock valued at $2,600,000 after buying an additional 190,000 shares during the last quarter. Hedge funds and other institutional investors own 45.55% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.